GLGuoyu Lan

Guoyu Lan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guoyu Lan has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Laihong Zhang

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China

    4 shared publications
  • Tengfei Guo

    Institute of Neurological and Psychiatric Disorders Shenzhen Bay Laboratory Shenzhen China

    3 shared publications
  • Yue Cai

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China

    3 shared publications
  • Zhengbo He

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China

    3 shared publications
  • Anqi Li

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong 999077, China

    2 shared publications
  • Jie Yang

    Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China

    2 shared publications

Latest Publications

  • Open Access

    Association of plasma p-tau and p-tau/Aβ ratio with Alzheimer's pathology

    by Xuhui Chen, Mingxing Jiang, Laihong Zhang, Jiayi Zhu, Anqi Li, Zhengbo He, Xin Zhou, Yalin Zhu, Chen Zhang, Cong Wang, et al.


  • Open Access

    Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma p ‐Tau217

    by Guoyu Lan, Laihong Zhang, Tengfei Guo

    Background: Phosphorylated tau217 ( p ‐tau217) are promising blood biomarkers for evaluating Alzheimer's disease (AD) neuropathology. This study investigated the performance of leading commercial p ‐tau217 assays in detecting and monitoring AD‐relevant processes. Method: We identified 363 non‐dementia ADNI participants with concurrent four distinct plasma p ‐tau217 assays (C2N, ALZpath, Janssen, and Lumipulse). Participants were categorized as negative, positive, and intermediate groups according to low and high thresholds of plasma p ‐tau217. We explored the differences in baseline and longitudinal changes in Aβ plaques, tau tangles, hippocampal atrophy, and cognitive decline across plasma p ‐tau217 stages. Result: The two‐cutoff approach improved plasma p ‐tau217 performance in identifying Aβ‐PET positivity, but four p ‐tau217 assays differed in percentages of the intermediate zone (Figure 1A). Regardless of specific assays, participants with abnormal plasma p ‐tau217 had significant abnormalities in baseline levels and longitudinal changes in Aβ‐PET, entorhinal tau‐PET, hippocampal volume, and PACC scores compared to those with normal plasma p ‐tau217 (Figures 1‐2). Participants with intermediate plasma p ‐tau217 also had greater baseline Aβ‐PET burden and more rapid accumulations of Aβ‐PET and entorhinal tau‐PET. Over a mean (SD) follow‐up duration of 6.8 (2.3) years, participants with abnormal plasma p ‐tau217 exhibited higher risks of developing dementia compared to those with normal or intermediate plasma p ‐tau217, with a larger percentage of dementia cases in the positive group (Figure 3). Notably, participants within intermediate zone also demonstrated greater risks of dementia than those with normal plasma p ‐tau217, when using plasma p ‐tau217 ALZ (Int, 11.6% vs. Neg, 4.2%), p ‐tau217 Janss (Int, 10.1% vs. Neg, 5.3%), and p ‐tau217 Fuji (Int, 9.9% vs. Neg, 2.2%), but not %p‐tau217 C2N (Int, 7.8% vs. Neg, 5.3%). Conclusion: Our findings highlight the advantages of plasma p ‐tau217 in detecting and monitoring dynamic disease progression. Confirmatory tests and longitudinal tracking are necessary for those with intermediate plasma p ‐tau217, as they may be at the early AD stage with high risks of rapid disease evolution. This categorized strategy may identify a novel target population for early pathological characteristics studies and interventions in AD. Incorporating high‐performance blood p ‐tau217 tests into clinical trials may improve AD diagnosis and enable larger‐scale screening of early‐stage patients with suspected AD pathophysiology for anti‐amyloid immunotherapies.

  • Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer’s disease in a multicenter and multiethnic aging population

    by Guoyu Lan, Mengjie Wang, Fernando Gonzalez-Ortiz, Laihong Zhang, Anqi Li, Binyin Li, Mingxing Jiang, Jie Yang, Xuhui Chen, Dai Shi, et al.

    Over 20% of patients with Alzheimer's disease (AD) worlwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (n = 425) and Huashan (n = 297), and the North American Alzheimer's Disease Neuroimaging Initiative cohort (n = 363). Plasma p-tau217 performed best in classifying Aβ-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of Aβ-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in Aβ-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.


  • Open Access

    Blood‐based glial reactivity modulates cerebral amyloid and tau deposition in Alzheimer's disease

    by Guoyu Lan, Anqi Li, Jie Yang, Laihong Zhang, Lili Fang, Yalin Zhu, Zhengbo He, Xin Zhou, Lin Liu, Pan Sun, et al.

    Background: Plasma biomarkers of Alzheimer’s disease (AD)‐related pathological changes are considered as proxies of their changes in the brain. Recent cohort studies reported very early changes in plasma astrocytic marker glial fibrillary acidic protein (GFAP) in the AD spectrum, which is relative to the onset of neuropathology. Little is known about the association between plasma soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and primary AD pathology. This study explored how GFAP and sTREM2 in plasma influence cortical β‐amyloid (Aβ) and tau deposition.Method: We measured the concentrations of plasma biomarkers by the Simoa or MSD platforms in a total of 285 individuals from the Greater‐Bay‐Area Healthy Aging Brain Study (GHABS) cohort, a large community‐based cohort study of older adults from China. All of them underwent Aβ PET imaging ([18F]‐D3FSP or [18F]‐florbetapir), and 104 individuals were additionally scanned for tau PET imaging. We investigated the modification effect of plasma glial biomarkers (GFAP and sTREM2) on Aβ PET and tau PET using generalized linear models, controlling for age, sex, and diagnosis.Result: Plasma GFAP but not sTREM2 interacted with Aβ42/Aβ40 and p‐Tau181 (Table 1), where higher GFAP levels were associated with steeper relations of lower Aβ42/Aβ40 and higher p‐Tau181 with elevated Aβ PET. Regarding tau PET, we found that higher plasma GFAP levels enhanced the association between plasma p‐Tau181 and tau PET. In contrast, higher plasma sTREM2 levels attenuated the associations of lower Aβ42/Aβ40 and higher p‐Tau181 with tau PET elevations. Congruent results were obtained when we used Aβ PET as the interaction term in the models. Furthermore, higher plasma sTREM2 levels also mitigated the association between plasma GFAP and tau PET but did not influence Aβ PET (Figure 1). At the voxel level, the association between plasma GFAP and tau PET was diminished and limited in individuals with above‐median sTREM2 levels versus individuals with below‐median sTREM2 levels.Conclusion: This study provides novel insights into the link between plasma glial biomarkers and cortical deposition of Aβ and tau aggregates, where plasma GFAP is linked to augmented Aβ and tau pathology, whereas plasma sTREM2 is linked to attenuated tau accumulation.

  • Open Access

    Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts

    by Kai Shao, Xiaochen Hu, Luca Kleineidam, Melina Stark, Slawek Altenstein, Holger Amthauer, Henning Boecker, Ralph Buchert, Katharina Buerger, Michaela Butryn, et al.

    INTRODUCTION: Subjective cognitive decline (SCD) in amyloid‐positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.METHODS: Eight hundred twenty‐one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed‐effects models.RESULTS: In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ− participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings.DISCUSSION: Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials.Highlights: SCD in amyloid‐positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.